<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04373785</url>
  </required_header>
  <id_info>
    <org_study_id>NG101m</org_study_id>
    <nct_id>NCT04373785</nct_id>
  </id_info>
  <brief_title>NG101m Adjuvant Therapy in Glioblastoma Patients</brief_title>
  <official_title>A Multi-Center Pilot/Phase I and Phase II Clinical Trial of NG101m Adjuvant Therapy in Newly Diagnosed Glioblastoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NeuGATE Theranostics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NeuGATE Theranostics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to evaluate the addition of NG101m adjuvant therapy to
      standard of care treatment of glioblastoma multiforme. All subjects will receive NG101m
      capsules along with the standard treatment of temozolomide and radiation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glioblastoma multiforme (GBM) is the most lethal form of malignant brain cancer, with about
      12,000 new cases diagnosed each in the the United States. The current standard treatment
      consists of maximal, safe resection, followed by radiation therapy of 60 Gray (Gy) with
      concomitant oral temozolomide (TMZ) for 6 weeks, then continue with six cycles of high-dose
      temozolomide. The median survival rate for newly diagnosed GBM patients is 14.6 months with a
      2-year overall survival (OS) rate of 27.2%. This clinical trial evaluates the 2-year OS of
      oral NG101m as an adjuvant therapy to chemoradiotherapy in newly diagnosed GBM subjects.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">June 2026</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Radiation: Radiotherapy Drug: Temozolomide Drug: NG101m</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-emergent adverse events and serious adverse events</measure>
    <time_frame>1 month</time_frame>
    <description>Assess safety and tolerability of NG101m as adjuvant therapy to chemoradiation therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>24 months</time_frame>
    <description>Assess efficacy of NG101m as adjuvant therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>24 months</time_frame>
    <description>Assess the duration of PFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response assessment in neuro-oncology (RANO) criteria</measure>
    <time_frame>24 months</time_frame>
    <description>Radiological response to adjuvant NG101m therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QoL)</measure>
    <time_frame>24 months</time_frame>
    <description>European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Identify and quantify immune/effector cells</measure>
    <time_frame>24 months</time_frame>
    <description>Cytokines measurement</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Newly Diagnosed Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>NG101m and standard treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concomittant therapy:
Radiation therapy, oral temozolomide, and oral NG101m
Adjuvant therapy:
Oral temozolomide and oral NG101m</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity-modulated radiation therapy</intervention_name>
    <description>Intensity-modulated radiation therapy (IMRT) in daily fractions of 2 Gy given 5 days per week for 6 weeks, for a total of 60 Gy.</description>
    <arm_group_label>NG101m and standard treatment</arm_group_label>
    <other_name>radiation therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Oral temozolomide (75 mg/m2), given 5 days per week, for 6 weeks during radiotherapy.
1 month after the discontinuation of radiotherapy, oral temozolomide is restarted at 150 to 200 mg/m2 for 5 days during each 28-day cycle for six cycles.</description>
    <arm_group_label>NG101m and standard treatment</arm_group_label>
    <other_name>Temodar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NG101m</intervention_name>
    <description>Oral NG101m capsule continuously twice daily.</description>
    <arm_group_label>NG101m and standard treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects ≥ 18 years of age

          -  Must be newly diagnosed with GBM

          -  Primary treatment must consist of a chemoradiation therapy (CRT) regimen

          -  Hemoglobin &gt; 9 g/dL

          -  White blood count 3,600 - 11,000/mm3

          -  Absolute neutrophil count (ANC) ≥ 1,500/mm3

          -  Absolute lymphocyte count (ALC) ≥ 1,000/mm3

          -  Platelet count 100,000/mm3

          -  BUN ≤ 1.5 times upper limit of normal

          -  Creatinine clearance rate &gt; 40 mL/min

          -  ALT ≤ 3 times upper limit of normal

          -  AST ≤ 3 times upper limit of normal

          -  Alkaline phosphatase ≤ 3 times upper limit of normal

          -  Total bilirubin ≤ 2.0 mg/dL

          -  Karnofsky Performance Status ≥ 70

          -  Must not be on any other alternative therapies

          -  Not pregnant

        Exclusion Criteria:

          -  Known hypersensitivity to meloxicam, famotidine, and/or caffeine or any of their
             derivatives or components

          -  Known allergy to vitamin A, vitamin D3, and/or L-citrulline

          -  Pregnant women

          -  Breastfeeding women

          -  Corticosteroid therapy that cannot be tapered down to a dose of 1 - 2 mg/day of
             dexamethasone or its equivalent

          -  History of immunodeficiency diseases or autoimmune diseases

          -  History of peptic ulcer disease or gastrointestinal perforation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yvonne Kew, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>NeuGATE Theranostics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thien Tran, PharmD</last_name>
    <phone>713-534-1300</phone>
    <email>TTran@NeuGATE.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yvonne Kew MD, PLLC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Thien Tran, Pharm.D.</last_name>
      <phone>713-534-1300</phone>
      <email>Thien@DrKew.com</email>
    </contact>
    <investigator>
      <last_name>Yvonne Kew, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 30, 2020</study_first_submitted>
  <study_first_submitted_qc>April 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2020</study_first_posted>
  <last_update_submitted>May 4, 2020</last_update_submitted>
  <last_update_submitted_qc>May 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

